Effect of HER2 IHC on enfortumab vedotin (EV) or EV+pembrolizumab (EVP) benefit in metastatic urothelial carcinoma.
Efficacy of pembrolizumab in advanced esophageal carcinoma: A systematic review and meta-analysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results